SEHK:3696
SEHK:3696Life Sciences

InSilico Medicine Deepens AI Drug Development With Qilu And ISM8969 Shift

InSilico Medicine Cayman TopCo (SEHK:3696) has agreed a major partnership with Qilu Pharmaceutical to co-develop small molecule drugs for cardiometabolic diseases using its Pharma.AI platform. The company is also reporting progress and fresh licensing activity around its ISM8969 program, which targets neurodegenerative disorders. Together, these updates mark a shift from a primarily software licensing approach toward more hands-on, co-development work in drug discovery. For you as an...
SEHK:3877
SEHK:3877Diversified Financial

Does CSSC (Hong Kong) Shipping’s (SEHK:3877) Subordinated Bond Raise Reframe Its Long-Term Capital Structure Strategy?

CSSC (Hong Kong) Shipping Company Limited previously announced a fixed-income offering of HK$2.34 billion in 0.75% subordinated, unsubordinated fixed-rate bonds due January 28, 2031. This sizable subordinated bond issue highlights the company’s focus on raising long-term funding through debt markets while preserving existing equity ownership. We will now examine how this HK$2.34 billion subordinated bond issuance shapes CSSC (Hong Kong) Shipping’s broader investment narrative and...
SEHK:1788
SEHK:1788Capital Markets

How Investors May Respond To Guotai Junan International (SEHK:1788) Forecasting a Sharp 2025 Profit Jump

In January 2026, Guotai Junan International Holdings Limited issued earnings guidance for 2025, projecting net profit of between HK$1,280 million and HK$1,380 million, a very large percentage increase from the approximately HK$351 million reported for 2024. The company attributed this sharp profit uplift to broad-based revenue gains across corporate finance, wealth management, asset management, and trading and investment, with especially strong contributions from equity capital markets and...